Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Altimmune (ALT) Gains from Sales and Divestitures (2017 - 2025)

Altimmune (ALT) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $286653.0 as the latest value for Q4 2025.

Quarterly Gains from Sales and Divestitures fell 0.8% to $286653.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $286653.0 through Dec 2025, down 0.8% year-over-year, with the annual reading at $286653.0 for FY2025, 0.8% down from the prior year.
Gains from Sales and Divestitures for Q4 2025 was $286653.0 at Altimmune, up from $267903.0 in the prior quarter.
The five-year high for Gains from Sales and Divestitures was $288977.0 in Q4 2024, with the low at $40364.0 in Q2 2022.
Average Gains from Sales and Divestitures over 4 years is $173370.5, with a median of $115018.0 recorded in 2023.
The sharpest move saw Gains from Sales and Divestitures surged 189.73% in 2024, then dropped 6.99% in 2025.
Over 4 years, Gains from Sales and Divestitures stood at $74000.0 in 2022, then skyrocketed by 55.43% to $115018.0 in 2023, then soared by 151.25% to $288977.0 in 2024, then fell by 0.8% to $286653.0 in 2025.
According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $286653.0, $267903.0, and $288977.0 for Q4 2025, Q3 2025, and Q4 2024 respectively.